Corvus Pharmaceuticals Inc CRVS
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $5.26
- Day Range
- $5.32–5.85
- 52-Week Range
- $1.05–6.15
- Bid/Ask
- $5.56 / $5.64
- Market Cap
- $352.79 Mil
- Volume/Avg
- 264,965 / 382,822
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Corvus Pharmaceuticals Inc is a clinical-stage biopharmaceutical engaged in developing drugs and antibodies that target the critical cellular elements of the immune system. It focuses on the development of immune modulator product candidates to treat COVID-19, T-cell lymphomas, other cancers, and autoimmune diseases. The company's primary product candidate is Soquelitinib (CPI-818), an oral, small-molecule drug that selectively inhibits ITK (interleukin-2-inducible T cell kinase). The other products include Ciforadenant (CPI-444) and Mupadolimab (CPI-006).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 28
- Website
- https://www.corvuspharma.com
Comparables
Valuation
|
Metric
|
CRVS
|
MGNX
|
CGON
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 6.89 | 3.89 | 4.42 |
Price/Sales | — | 5.66 | 244.06 |
Price/Cash Flow | — | — | — |
Price/Earnings
CRVS
MGNX
CGON
Financial Strength
|
Metric
|
CRVS
|
MGNX
|
CGON
|
|---|---|---|---|
Quick Ratio | 3.55 | 2.53 | 46.66 |
Current Ratio | 3.62 | 2.71 | 47.57 |
Interest Coverage | — | −128.87 | — |
Quick Ratio
CRVS
MGNX
CGON
Profitability
|
Metric
|
CRVS
|
MGNX
|
CGON
|
|---|---|---|---|
Return on Assets (Normalized) | −38.51% | −59.21% | −15.24% |
Return on Equity (Normalized) | −46.17% | −120.96% | −26.61% |
Return on Invested Capital (Normalized) | −48.24% | −102.88% | −25.60% |
Return on Assets
CRVS
MGNX
CGON
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Cyhhlfpqr | Nmt | $512.4 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Kpcjxvbs | Hzrhtv | $117.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Zrxfjdbsy | Gxpnpq | $111.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Jclbrdqp | Nshdkf | $34.4 Bil | |||
| argenx SE ADR
ARGX
| Qtwcryyrh | Byd | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Ccvqrtpf | Kvcdd | $29.2 Bil | |||
| Moderna Inc
MRNA
| Wrwxssdqp | Vrkvx | $23.1 Bil | |||
| United Therapeutics Corp
UTHR
| Sswgfpj | Kzsb | $15.8 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Xsjfldpjw | Xdbqvf | $13.2 Bil | |||
| Incyte Corp
INCY
| Xkrknbb | Wslkr | $13.0 Bil |
United States